However, our study was limited by the fact that the available volume of plasma for the free methylated TMEM240 analysis was 200 μL, which is much less than the 3.5 mL of plasma used for the analysis of free methylated SEPT9. Approximately 90% of CRC patients exhibit TMEM240 hypermethylation, and the detection of circulating methylated TMEM240 will still improve early diagnosis and provide a noninvasive method to monitor the residual tumor burden after treatment. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.